Hepcidin in morbidly obese women with non-alcoholic fatty liver disease

PLoS One. 2017 Oct 24;12(10):e0187065. doi: 10.1371/journal.pone.0187065. eCollection 2017.

Abstract

Background: Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in Western countries. Both iron and lipid metabolism seem to be involved in its pathogenesis. We aimed to assess the relationship between levels of hepcidin, the master iron-regulatory protein, in plasma and the presence of NAFLD in morbidly obese (MO) patients, and to investigate the association between the hepatic expression of the main iron and lipid metabolism -related genes.

Materials and methods: Enzyme-linked immunosorbent assay was used to measure plasma hepcidin levels in 49 normal-weight control women, 23 MO women with normal liver (NL) histology and 46 MO women with NAFLD. The mRNA expression of hepcidin, the main iron metabolism-related genes, and the main lipid-metabolism genes was quantified by qRT-PCR in liver biopsies from members of the MO group undergoing bariatric surgery.

Results: Circulating hepcidin levels were significantly greater in MO than in normal-weight control women. However, there were no significant differences between MO women with NL and those with NAFLD. PCR analysis showed increased expression of hepcidin, FPN1, TfR1 and TfR2 in the liver of MO NAFLD women compared to those with NL. Moreover, a positive association of hepatic hepcidin mRNA expression and the iron metabolism-related genes was found with some key genes involved in the lipid metabolism.

Conclusion: These findings suggest that circulating hepcidin levels are associated with obesity but not with the presence of NAFLD. However, the hepatic expression of hepcidin and the iron metabolism-related genes seem to play a role in regulating lipid metabolism pathways in liver, which has implications for NAFLD pathogenesis.

MeSH terms

  • Adult
  • Body Mass Index
  • Enzyme-Linked Immunosorbent Assay
  • Female
  • Hepcidins / blood*
  • Humans
  • Middle Aged
  • Non-alcoholic Fatty Liver Disease / complications
  • Non-alcoholic Fatty Liver Disease / drug therapy*
  • Obesity, Morbid / complications
  • Obesity, Morbid / drug therapy*

Substances

  • Hepcidins

Grants and funding

This study was supported by the Fondo de Investigación Sanitaria (FEDER, Grant Number PI116/00498 to Teresa Auguet), the Agència de Gestió d’Ajuts Universitaris de Recerca (AGAUR 2009 SGR 959 to Cristóbal Richart), the Grup de Recerca en Medicina Aplicada URV (2016 PFR-URV-B2-72 to Cristóbal Richart) and the Fundación Biociencia. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.